We are monitoring the impact of COVID-19 on MEA Antivenom Market Get in touch with us for detailed analysis Know More
Pulished Date February, 2020
ID: 1506
Share on
Share on

Middle East and Africa Antivenom Market Research Report – Segmented By Type, Animal and Country (KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA) - Industry Analysis, Size, Share, Trends & Growth Forecast (2020 to 2025)

Pulished: February, 2020
ID: 1506
Pages: 145

MEA Antivenom Market Size (2020 to 2025)

The Antivenom Market size in the Middle-East & Africa is expected to be worth USD 0.19 billion by 2025 from USD 0.14 billion in 2020, growing at a CAGR of 6.67% between 2020 to 2025.

Antivenom is described as the biological product that detoxifies the poisoning of venomous bites. Antivenom is prepared from animals' milking venom such as snakes, spiders, scorpions, and other venomous animals. Venomous bites result in certain clinical conditions such as secretion of excessive saliva, muscle weakness, breathing problems, and other difficulties that may also lead to death. It is estimated that approximately 35,000-55,000 people are recorded with snake bites annually in Africa. The manufacturers developed several Antivenom products to overcome poisonous effects after venomous bites, including vaccines and hyperimmune sera.

The growing number of venomous animal bite cases, rising demand for antivenom products, the emergence of new Pan-African polyvalent antivenom products using modern proteomic & antivenomics tools, and the presence of antivenom financing systems are driving the growth of the Middle-East & Africa Antivenom Market.

However, the dearth of antivenom products, high manufacturing costs of antivenom products, decreasing antivenom production, and limited adoption of antivenom products are hampering the growth of the Middle-East & Africa Antivenom Market.

This research report on the Middle East and Africa Antivenom Market has been segmented & sub-segmented the market into the following categories:

By Type:

  • Vaccines
  • Hyperimmune Sera
    • Homologous
    • Heterologous

By Animal: 

  • Snakes
  • Scorpions
  • Spiders
  • Others

By Country: 

  • KSA
  • UAE
  • Israel
  • rest of GCC countries
  • South Africa
  • Ethiopia
  • Kenya
  • Egypt
  • Sudan
  • rest of MEA

Companies dominating the MEA Antivenom Market are Instituto Bioclon, S.A. de C.V. (Mexico), Pfizer AG (Switzerland), CSL Limited (Australia), F. Hoffmann-La Roche Ltd. (Switzerland), Merck & Co., Inc. (U.S.), Rare Disease Therapeutics, Inc. (U.S.), Vins Bioproducts Limited (India), BTG Plc (U.K.), Incepta Vaccine Ltd. (Bangladesh) and Bharat Serum.

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                             

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 Type                              

                                5.1.1 Introduction           

                                5.1.2 Vaccines  

                                5.1.3 Hyperimmune Sera             

                                                5.1.3.1 Homologous

                                                5.1.3.2 Heterologous

                                5.1.4 Y-o-Y Growth Analysis, By type       

                                5.1.5 Market Attractiveness Analysis, By Type     

                                5.1.6 Market Share Analysis, By Type      

                5.2 Animal                          

                                5.2.1 Introduction           

                                5.2.2 Snakes      

                                5.2.3 Scorpions

                                5.2.4 Spiders     

                                5.2.5 Others      

                                5.2.6 Y-o-Y Growth Analysis, By Animal  

                                5.2.7 Market Attractiveness Analysis, By Animal

                                5.2.8 Market Share Analysis, By Animal 

6. Geographical Analysis                                              

                6.1 Introduction                              

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Type

                                                6.1.3.2 By Animal

                                6.1.4 Market Attractiveness Analysis      

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By Type

                                                6.1.4.2 By Animal

                                6.1.5 Market Share Analysis        

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 By Type

                                                6.1.5.2 By Animal

                6.2 Middle-East                                

                6.3 Africa                            

7.Strategic Analysis                                        

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental      

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services

                                7.2.5 Competitive Rivalry within the Industry      

8.Market Leaders' Analysis                                          

                8.1 Instituto Bioclon, S.A. de C.V.                              

                                8.1.1 Overview

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Pfizer AG                     

                8.3 CSL Limited                 

                8.4 Roche                           

                8.5 Merck & Co                

                8.6 Rare Disease Therapeutics, Inc.                         

                8.7 Vins Bioproducts Limited                      

                8.8 BTG Plc                         

                8.9 Incepta Vaccine Ltd                 

                8.10 Bharat Serim and Vaccines Limited (BSV)                    

9.Competitive Landscape                                            

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                        

                9.3 Agreements, collaborations and Joint Ventures                          

                9.4 New Product Launches                          

10.Market Outlook and Investment Opportunities                                           

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Middle East & Africa Antivenom Market, By Type, From 2020 to 2025 (USD Million)
  2. Middle East & Africa Vaccines Market, By Region, From 2020 to 2025 (USD Million)
  3. Middle East & Africa Hyperimmune Sera Market, By Region, From 2020 to 2025 (USD Million)
  4. Middle East & Africa Antivenom Market, By Animal, From 2020 to 2025 (USD Million)
  5. Middle East & Africa Snakes Market, By Region, From 2020 to 2025 (USD Million)
  6. Middle East & Africa Scorpions Market, By Region, From 2020 to 2025 (USD Million)
  7. Middle East & Africa Spiders Market, By Region, From 2020 to 2025 (USD Million)
  8. Middle East & Africa Others Market, By Region, From 2020 to 2025 (USD Million)
  9. Middle East Antivenom Market, By Type, From 2020 to 2025 (USD Million)
  10. Middle East Antivenom Market, By Animal, From 2020 to 2025 (USD Million)
  11. Africa Antivenom Market, By Type, From 2020 to 2025 (USD Million)
  12. Africa Antivenom Market, By Animal, From 2020 to 2025 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 2875

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample